We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+18.81%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$2.59B
AUM Growth
+$289M
Cap. Flow
+$97.5M
Cap. Flow %
3.76%
Top 10 Hldgs %
46.26%
Holding
80
New
11
Increased
26
Reduced
24
Closed
16

Top Buys

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$75.7M
2
ATRA icon
Atara Biotherapeutics
ATRA
+$51.8M
3
XNCR icon
Xencor
XNCR
+$48.5M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$48.4M
5
WCG
Wellcare Health Plans, Inc.
WCG
+$39.6M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$89.8M
2
AZN icon
AstraZeneca
AZN
+$70.2M
3
CELG
Celgene Corp
CELG
+$68.1M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$61.8M
5
CTLT
CATALENT, INC.
CTLT
+$34.2M

Sector Composition

Rank Sector Weight
1 Healthcare 92.32%
2 Financials 0.74%
3 Communication Services 0.37%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CSLT
76
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
– –
-10,229
Closed -$38K
CASC
77
DELISTED
Cascadian Therapeutics, Inc.
CASC
– –
-649,446
Closed -$2.4M
CELG
78
DELISTED
Celgene Corp
CELG
– –
-653,000
Closed -$68.1M
1 2 3
4

Similar funds

KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Redmile Group's Q1 2018 Portfolio in Review

As of Q1 2018, Redmile Group held 80 positions worth $2.59B, up 13% from $2.3B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Redmile Group deployed $97.5M of net new capital in Q1 2018, opening 11 new positions and adding to 26 existing holdings. Its largest new stake was AveXis, Inc. Common Stock: 636,900 shares worth $78.7M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 93% a quarter earlier, followed by Financials and Communication Services.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $30.3M trimmed.

  • Redmile Group's largest Q1 2018 buy was AveXis, Inc. Common Stock: 636,900 shares worth $78.7M.
  • Redmile Group added most to Atara Biotherapeutics in Q1 2018, an estimated $51.8M increase.
  • Redmile Group's biggest Q1 2018 reduction was Array Biopharma Inc, cutting an estimated $30.3M.
  • Redmile Group fully exited Clovis Oncology, Inc. in Q1 2018, selling an estimated $89.8M.
  • Redmile Group's ten largest holdings make up 46% of its $2.59B portfolio in Q1 2018.
  • Redmile Group opened 11 new positions and closed 16 in Q1 2018.
  • Redmile Group's portfolio value rose 13% quarter-over-quarter to $2.59B.

Based on Redmile Group's 13F filing for Q1 2018, filed 15 May 2018.